Adverum Biotechnologies Inc (NASDAQ:ADVM) had a decrease of 16.16% in short interest. ADVM’s SI was 1.97 million shares in December as released by FINRA. Its down 16.16% from 2.35M shares previously. With 1.63 million avg volume, 1 days are for Adverum Biotechnologies Inc (NASDAQ:ADVM)’s short sellers to cover ADVM’s short positions. The stock decreased 1.91% or $0.07 during the last trading session, reaching $3.59. About 388,559 shares traded. Adverum Biotechnologies, Inc. (NASDAQ:ADVM) has risen 13.23% since December 16, 2017 and is uptrending. It has outperformed by 13.23% the S&P500. Some Historical ADVM News: 01/05/2018 – Adverum Bio Presenting at ASGCT Meeting May 17; 06/03/2018 Adverum Biotechnologies 4Q Loss/Shr 32c; 10/05/2018 – Adverum Bio Presenting at Conference May 17; 03/05/2018 – ADVERUM BIOTECHNOLOGIES – LEONE PATTERSON, SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, APPOINTED INTERIM CHIEF EXECUTIVE OFFICER OF ADVERUM; 17/05/2018 – Adverum Bio 33.4% Owned by Hedge Funds; 03/05/2018 – ADVERUM BIOTECHNOLOGIES INC ADVM.O – BOARD AND AMBER SALZMAN, CHIEF EXECUTIVE OFFICER MADE A MUTUAL DETERMINATION THAT SALZMAN STEP DOWN; 03/05/2018 – Adverum Biotechnologies: Financial Chief Leone Patterson Named Interim CEO; 15/05/2018 – Rock Springs Capital Management Buys 1.4% of Adverum Bio; 03/05/2018 – ADVERUM BIOTECHNOLOGIES CEO SALZMAN TO STEP DOWN; 01/05/2018 – ADVM: PRECLINICAL DATA ON ADVM-022 GENE THERAPY IN WET AMD
Nine Masts Capital Ltd decreased Jd Com Inc (Put) (JD) stake by 68.23% reported in 2018Q3 SEC filing. Nine Masts Capital Ltd sold 1,074 shares as Jd Com Inc (Put) (JD)’s stock declined 22.69%. The Nine Masts Capital Ltd holds 500 shares with $450,000 value, down from 1,574 last quarter. Jd Com Inc (Put) now has $32.08B valuation. The stock decreased 2.38% or $0.54 during the last trading session, reaching $22.17. About 14.84 million shares traded. JD.com, Inc. (NASDAQ:JD) has declined 46.21% since December 16, 2017 and is downtrending. It has underperformed by 46.21% the S&P500. Some Historical JD News: 16/04/2018 – JD.COM- VARIOUS MARGINS CALCULATED FROM THE FINANCIAL INFORMATION REPORTED IN THE FINANCIAL STATEMENTS “ARE ACCURATE”; 24/04/2018 – E-Commerce: Global Markets to 2022 – Leading Players are Alibaba, Amazon.com, Apple, JD.com and Walmart – ResearchAndMarkets.com; 08/05/2018 – JD.COM SEES FY REV. +29% TO +33%; 16/03/2018 – JD.com’s finance arm is fundraising at a $20 billion valuation; 24/04/2018 – LESHI INTERNET INFORMATION SAYS ITS TIANJIN UNIT SIGNS AGREEMENT WITH COMPANY RELATED TO JD.COM ON COOPERATION ON VARIOUS FRONTS SUCH AS E-COMMERCE; 05/03/2018 MFS Research International Fund Adds Dufry, Exits JD.com; 29/05/2018 – JD.com tests L4 autonomous truck in US, sources say; 09/03/2018 – JD.COM TO ASSIST VILLAGERS IN CHINA’S IMPOVERISHED REGIONS: LIU; 15/05/2018 – JD.com Invests US$306m in ESR; 16/03/2018 – CHINA’S JD.COM JD.O FINANCE UNIT LOOKING TO RAISE ABOUT $1.9 BLN THAT COULD VALUE IT AT MORE THAN $20 BLN
More notable recent Adverum Biotechnologies, Inc. (NASDAQ:ADVM) news were published by: Globenewswire.com which released: “Adverum Biotechnologies Appoints Mike Fitzgerald as Vice President, Human Resources – GlobeNewswire” on December 03, 2018, also Nasdaq.com with their article: “Adverum Announces First Patient Dosed in OPTIC Phase 1 Trial of ADVM-022 Gene Therapy in Wet Age-Related Macular Degeneration – Nasdaq” published on November 19, 2018, Globenewswire.com published: “Adverum Biotechnologies Announces Publication of Preclinical Long-Term Expression and Efficacy Data in Molecular Therapy – GlobeNewswire” on December 03, 2018. More interesting news about Adverum Biotechnologies, Inc. (NASDAQ:ADVM) were released by: Nasdaq.com and their article: “What Bargains? Play 5 Stocks With Rising P/E Instead – Nasdaq” published on December 12, 2018 as well as Seekingalpha.com‘s news article titled: “Adverum Biotechnologies announces IND active for ADVM-022 to treat wAMD – Seeking Alpha” with publication date: August 30, 2018.
Adverum Biotechnologies, Inc., a gene therapy company, discovers and develops novel medicines for patients suffering from rare diseases or diseases of eye. The company has market cap of $225.70 million. The firm has a pipeline that includes product candidates to treat wet age-related macular degeneration , alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. It currently has negative earnings. The Company’s lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development of new anti-VEGF gene therapy candidates for wAMD diseases; and ADVM-043, which is in patient enrollment in a phase 1/2 trial for the treatment of A1AT.
Nine Masts Capital Ltd increased Nuveen Floating Rate Income (JFR) stake by 159,600 shares to 304,200 valued at $3.16M in 2018Q3. It also upped Neuberger Berman Mlp Income stake by 67,300 shares and now owns 78,500 shares. Invesco Sr Income Tr (VVR) was raised too.
Among 7 analysts covering JD.com (NASDAQ:JD), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. JD.com had 10 analyst reports since August 17, 2018 according to SRatingsIntel. M Partners maintained JD.com, Inc. (NASDAQ:JD) on Friday, December 7 with “Buy” rating. On Friday, October 12 the stock rating was maintained by UBS with “Buy”. The rating was maintained by Nomura with “Buy” on Friday, August 17. KeyBanc Capital Markets downgraded the stock to “Sector Weight” rating in Monday, October 29 report. Macquarie Research downgraded the shares of JD in report on Tuesday, November 20 to “Neutral” rating. The stock has “Neutral” rating by Mizuho on Thursday, December 13. The rating was maintained by KeyBanc Capital Markets with “Overweight” on Friday, August 17. On Friday, August 17 the stock rating was maintained by UBS with “Buy”. Nomura downgraded the shares of JD in report on Tuesday, November 20 to “Neutral” rating. Stifel Nicolaus maintained JD.com, Inc. (NASDAQ:JD) on Friday, August 17 with “Buy” rating.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.